A letter posted to the site of the FDA indicates that the agency approved the new drug application, or NDA, submitted by Teva Neuroscience, as amended, for the use of Austedo XR 6, 12, and 24 mg tablets for the treatment of chorea associated with Huntington’s disease and tardive dyskinesia. Reference Link
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on TEVA:
- Axsome facing Auvelity IP challenge ‘not a surprise,’ says BofA
- Axsome received Paragraph IV certification notice on Auvelity ANDA from Teva
- Teva settles price-fixing claims in Florida for $6.73M
- Teva price target raised to $14 from $13 at Barclays
- Israel’s TEVA, PERI Tank on Q4 Earnings; IZRL in Focus